NRBO
Income statement / Annual
Last year (2024), NeuroBo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, NeuroBo Pharmaceuticals, Inc.'s net income was -$27.59 M.
See NeuroBo Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$7.00 K
|
$28.00 K
|
$72.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$7.00 K
|
-$28.00 K
|
-$72.00 K
|
-$67.00 K
|
-$17.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.55 M
|
$9.15 M
|
$2.75 M
|
$6.55 M
|
$21.87 M
|
$5.32 M
|
$14.31 M
|
$22.69 M
|
$8.74 M
|
$3.99 M
|
| General & Administrative Expenses |
$7.26 M
|
$6.73 M
|
$8.64 M
|
$8.75 M
|
$7.85 M
|
$2.70 M
|
$8.49 M
|
$10.44 M
|
$5.96 M
|
$3.18 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.26 M
|
$6.73 M
|
$8.64 M
|
$8.75 M
|
$7.85 M
|
$2.70 M
|
$8.49 M
|
$10.44 M
|
$5.96 M
|
$3.18 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$83.00 K
|
$0.00
|
-$1.00 K
|
$12.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$28.81 M
|
$15.88 M
|
$11.42 M
|
$15.30 M
|
$29.72 M
|
$20.18 M
|
$22.81 M
|
$33.12 M
|
$14.70 M
|
$7.17 M
|
| Cost And Expenses |
$0.00
|
$15.89 M
|
$11.42 M
|
$15.30 M
|
$29.72 M
|
$20.18 M
|
$22.81 M
|
$33.12 M
|
$14.70 M
|
$7.17 M
|
| Interest Income |
$920.00 K
|
$461.00 K
|
$2.19 K
|
$14.00 K
|
$39.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2.19 M
|
$0.00
|
$39.00 K
|
$22.00 K
|
$654.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$7.00 K
|
$28.00 K
|
$48.00 K
|
$46.00 K
|
$17.00 K
|
$6.67 M
|
$60.00 K
|
-$17.00 K
|
$2.01 M
|
| EBITDA |
-$28.81 M |
-$12.46 M |
-$11.39 M |
-$15.24 M |
-$29.61 M |
-$21.17 M |
-$15.49 M |
-$33.09 M |
-$14.50 M |
-$6.07 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.22 M
|
$3.42 M
|
$5.66 M
|
$14.00 K
|
$38.00 K
|
-$1.14 M
|
-$832.00 K
|
-$291.00 K
|
$110.00 K
|
-$953.00 K
|
| Income Before Tax |
-$27.59 M
|
-$12.47 M
|
-$13.97 M
|
-$15.28 M
|
-$29.68 M
|
-$21.31 M
|
-$15.53 M
|
-$33.42 M
|
-$14.59 M
|
-$9.03 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$654.00 K
|
$286.00 K
|
-$137.00 K
|
$0.00
|
| Net Income |
-$27.59 M
|
-$12.47 M
|
-$13.97 M
|
-$15.28 M
|
-$29.68 M
|
-$21.31 M
|
-$23.64 M
|
-$33.42 M
|
-$14.59 M
|
-$9.03 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.56 |
-2.46 |
-19.01 |
-157.85 |
-439.2 |
-1030.5 |
-166.8 |
-2421.73 |
-1883.28 |
-1277.45 |
| EPS Diluted |
-3.56 |
-2.46 |
-19.01 |
-157.85 |
-439.2 |
-1030.5 |
-166.8 |
-2421.73 |
-1883.28 |
-1277.45 |
| Weighted Average Shares Out |
$77.57 M
|
$5.07 M
|
$321.70 K
|
$96.43 K
|
$67.57 K
|
$21.00 K
|
$17.71 K
|
$13.80 K
|
$7.75 K
|
$7.07 K
|
| Weighted Average Shares Out Diluted |
$77.57 M
|
$5.07 M
|
$321.70 K
|
$96.43 K
|
$67.57 K
|
$21.77 K
|
$17.71 K
|
$13.80 K
|
$7.75 K
|
$7.07 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
